CMTM3 and Alzheimer disease: IPA revealed activation of IL-1B, IL-6, TNF, and APP and downregulation of CMTM3, Nrf2, and Sirt-1 signaling in SAMP8 mice, while FMN activated CREB1–BDNF signaling growth factors along with the downregulation of TP53 to combat AD-like pathology.